Infection-induced renal calculi  by Griffith, Donald P.
Kidney International, Vol. 21(1982), pp. 422—430
NEPHROLOGY FORUM
Infection-induced renal calculi
Principal discussant: DONALD P. GRIFFITH
Baylor College of Medicine and Texas Medical Center, Houston, Texas
Case presentation
An obese, 49-year-old woman was admitted to the New England
Medical Center (NEMC) because of nausea, vomiting, severe leg
cramps, and intermittent dizziness for one week. In addition, she
thought that her daily urine volume had been decreasing during the few
days prior to admission. Mild hypertension had been treated for 5 years
with a thiazide diuretic, but she had no history of urinary tract infection,
renal calculi, hematuria, or analgesic abuse.
Physical examination revealed a blood pressure of 90/60mm Hg and a
pulse of 110 per minute in the supine position with marked orthostatic
changes. The temperature was 36.5° C, and the respiratory rate was 28/
mm. She weighed 99.9 kg. Funduscopic examination revealed mild
arteriolar narrowing and arteriovenous nicking. The lungs were clear.
Cardiac, abdominal, pelvic, and neurologic examinations were unre-
markable.
Laboratory findings revealed a hemoglobin of 16.1 g/dl, a hematocrit
of 49%, and a white blood cell count of 23,800/mm3 with 88% polymor-
phonuclear leukocytes; the platelet count was 687,000/mm3. The serum
sodium was 116 mEq/liter; potassium, 8.3 mEq/liter; chloride, 77 mEq/
liter; total C02, 10mm/liter; BUN, 192 mg/dl; serum creatinine, 8.8 mg/
dl; serum calcium, 10.0 mg/dl; phosphorus, 12.9 mg/dl; uric acid, 16.5
mg/dl. Results of urinalysis revealed a specific gravity of 1.012, a pH of
7.5, and 3+ heme and 3+ protein on dipstick examination. Microscopic
examination of the spun sediment revealed numerous red and white
blood cells but no casts or renal tubular cells. The unspun urine
sediment contained numerous gram-negative rods. The electrocardio-
gram revealed tall, peaked precordial T waves. A chest x-ray showed
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clear lung fields, and a plain film of the abdomen revealed massive
bilateral staghorn calculi.
The patient was treated for hyperkalemia with an infusion of glucose,
insulin, and sodium bicarbonate, and for volume depletion with intrave-
nous saline. Peritoneal dialysis was initiated. Gentamicin and ampicillin
therapy were begun for presumed gram-negative sepsis. Urine culture
subsequently grew Proteus mirabilis sensitive to ampicillin, and genta-
micin administration was discontinued. Blood cultures were negative.
The patient's weight increased to 103.8 kg; the BUN fell to 86 mg/dl,
and the serum creatinine decreased to 4.3 mg/dl over the next 36 hours.
The BUN and serum creatinine fell to 25 mg/dl and 2.8 mg/dl respective-
ly over the next week without additional dialysis.
A subsequent intravenous urogram disclosed that both kidneys were
18 cm in length and that both contained staghorn calculi. The ureters
were not visualized but the contrast medium did reach the bladder. A
renal echogram showed no ureteral obstruction, and a renal scan
demonstrated good blood flow to both kidneys. A retrograde pyelogram
revealed no evidence of stone or tumor in the ureters or the pelvis.
During cystoscopy, the bladder mucosa appeared white and granular
with cystic areas.
The patient was discharged 13 days after admission with a BUN of 18
mg/dl, a serum creatinine of 3.0 mg/dl; and a white blood cell count of
7000/mm3; she was receiving only oral ampicillin. She was advised to
return for evaluation but failed to do so until one year later at which
time she was doing well. Urine culture at that time revealed greater than
100,000 cot/mI of mixed fecal flora; the BUN was 63 mg/dl and the
serum creatinine was 3.8 mg/dl.
Discussion
DR. DONALD P. GRIFFITH (Associate Professor, Department
of Urology, Baylor College of Medicine, Texas Medical Center,
Houston, Texas): This patient has large, bilateral obstructing
staghorn calculi. She also has acute and chronic pyelonephritis
secondary to urea-splitting bacteria, probable pyonephrosis,
and advanced renal failure. In many ways her renal disease
parallels a malignant process: her disease is morbid, progres-
sive, probably incurable, and life threatening. Some clinicians
have referred to this condition as 'stone cancer." This patient
has infection-induced stones, but she may also have coexistent
metabolic stones and anatomic abnormalities such as vesicoure-
teral reflux.
I am hesitant to discuss the management of this particular
patient because therapy is greatly influenced by complicating
factors (such as obesity and cardiopulmonary status), socioeco-
nomic factors, and patient reliability. Clearly, however, this
patient cannot be cured with medical treatment, and she is
likely to receive only short-term palliation from antimicrobial
agents. Without surgery, she will progressively lose renal
function until she becomes a candidate for chronic dialysis or
transplantation. The advanced nature of her renal failure re-
duces the outlook for successful surgical treatment of her
stones. Surgical removal of all calculi from both kidneys with
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concomitant antimicrobial treatment, however, offers the po-
tential for complete eradication of her urinary infection and for
stabilization of renal function. If residual calculi remain postop-
eratively, persistent infection is virtually assured. But noncura-
tive surgical treatment may offer significant palliation, particu-
larly if recurrent stone formation can be retarded with long-term
antibacterial therapy.
Let me use this patient to initiate a review of infection-
associated renal lithiasis. The association of stones and putre-
faction has been known since Hippocrates, who cautioned his
followers not to drain loin abscesses, but rather to leave such
treatment to itinerant barber surgeons [1]. His admonitions
probably resulted from the high mortality associated with the
operation. In 1817, Marcet pointed out that "the alkalinization
that attends putrefaction of urine unavoidably results in crystal-
lization of dissolved urinary phosphates" [21. Brown, in 1901,
made clinical observations that supported Marcet's hypothesis
[3]. Hagar and McGrath suggested in 1925 that urease was the
biochemical basis for stone formation in infected urine [4]. In
1926, Sumner purified and isolated urease. He showed that
urease was a protein and that it catalyzed the hydrolysis of
urea. His discoveries ushered in the age of enzymology—an
achievement for which he subsequently received a Nobel prize
[5].
The pathophysiology of stone formation provides a rational
basis for classifying patients with the combination of stones and
infection. We recognize two distinct pathogenetic sequences:
one in which infection is primary and stone formation is the
secondary consequence, and another in which stone formation
and urinary infection coexist as separate entities. I will refer to
the first type as infection-induced stones and the second type as
infection-associated stones.
The pathogenesis of infection-induced stones is well defined.
Numerous observations have confirmed the historic concepts
that bacteria induce crystallization of struvite (MgNH4PO4-
6H20) and carbonate apatite [Ca10(P04)6C03]. As shown in
Figure 1, crystallization occurs as a consequence of the hydrol-
ysis of urea by bacterial urease [6—9]. When urea is split in
urine, an optimal milieu for precipitation is created: urinary pH
is high (often 8 to 9), and the urine is rich in calcium,
magnesium, ammonium, and phosphate. Figure 2 shows how
these changes in urinary composition evolve as urea is hydro-
lyzed by the bacterial enzyme urease. It is primarily and
perhaps only urease-producing bacteria that induce stone for-
mation (Table 1). It should be pointed out that infection-induced
stones can form primarily or secondarily upon preexistent
metabolic stones. In fact, approximately 50% of patients with
infection-induced stones have coexistent metabolic stones.
For completeness, let me mention infection-associated
stones. These stones can have any chemical composition (calci-
um oxalate or cystine, for example), Infection occurs indepen-
dently of the stone's presence. However, the foreign body acts
as a nidus and harbors and perpetuates the infection. The
bacteria have little or nothing to do with stone formation. The
principal part of my discussion today will center around the
problem of infection-induced stones.
Clinical manifestations. Patients with infection-induced uri-
nary stones typically have branched renal calculi and urinary
infection. Such stones may be found incidentally during evalua-
tion of bacteriuria or cystitis. Conversely, the patient may
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Fig. 1. Hydrolysis of urea by the bacterial enzyme urease.
present with acute pyelonephritis as the first manifestation; this
was evidently the case in the patient presented today. The
associated bacteriuria is usually, although not invariably, a
urease-producing bacterial species. Occasionally, only a ure-
ase-negative bacterial species can be isolated from urine; how-
ever, a urease-producing bacterial species usually can be cul-
tured from inside the stone. Such discrepancies probably are
due to variations in in vitro bacterial growth when mixed
cultures are present.
Patients who are not cured by traditional medical and surgical
treatment face a progressive clinical course such as that illus-
trated by the patient presented today. In fact, the consequences
of this kind of stone disease are so serious that many urologists
refer to it as "malignant stone disease" or even "stone can-
cer." Patients with disabilities—such as spinal cord injury or
urinary diversion—who are particularly susceptible to urinary
infection, are also particularly difficult to cure. The majority of
deaths in paraplegic veterans of World War II and the Korean
conflict occurred as a consequence of chronic urea-splitting
pyelonephritis, recurrent renal calculi, and chronic renal failure
[10].
Treatment with antimicrobial agents improves symptoms
associated with acute pyelonephritis. Long-term oral treatment
with antimicrobial agents is not very successful, however, in
maintaining sterile urine when large renal calculi are present
[11]. Persistent or recurrent infection is usually associated with
stone recurrence, stone growth, or both.
Urease-producing bacteria often are associated with stones
that contain a soft, mushy, gelatinous matrix [12, 13]. This
matrix is composed of mucoproteinaceous debris that contains
desquamated cells, leukocytes, and red cells. This matrix is
radiolucent, but it can mineralize rapidly with calcium and
magnesium phosphate (Fig. 3). The source of the matrix is
unknown, but it may be derived from uroepithelial secretions.
Ureteral obstruction is a relatively uncommon manifestation
of infection-induced stones. When it is present, however,
pyonephrosis and septicemia can occur. In such instances,
immediate drainage of the pyonephrosis is warranted. The
preferred method of drainage is either retrograde placement of
ureteral catheters or percutaneous nephrostomy. Before and
after drainage, concomitant therapy should include antimicrobi-
al agents, intravenous fluids, and other adjunctive measures.
Treatment. Cure can only be achieved by the removal of all
foreign bodies (calculi, matrices, and catheters) and by eradica-
tion of the infection [14]. Postoperatively, long-term antimicro-
bial therapy with agents known to be effective against the
specific organism is needed in most cases to eradicate infection.
Repeated urine cultures over many months are mandatory.
Using "at home" culture techniques, patients can monitor the
effectiveness of antimicrobial treatment themselves. These
methods include Uricult (Medical Technology Corp., Hacken-
sack, New Jersey) and Bacturcult (Wampete Corp., Cranberry,
New Jersey 08512).
Operative removal of branched renal calculi requires that the
surgeon have considerable urologic experience and expertise so
that as much kidney tissue as possible can be preserved.
Several adjunctive techniques are used, including renal hypo-
thermia, intraoperative renal radiography, and intraoperative
nephroscopy to facilitate removal of all calculous material. The
details of such techniques have recently been reviewed [141.
Palliative medical treatment is warranted when stones cannot
be eliminated completely or when infection persists even after
all stones have been removed. Chronic antimicrobial therapy
probably retards stone formation if it achieves sterile urine.
Penicillin has been advocated for Proteus mirabilis urinary
infection because the drug concentration achieved in the urine
exceeds the minimum inhibitory concentration of more than
90% of P. mirabilis strains [15]. Indeed, long-term, perhaps
lifetime, treatment may sterilize the urine. Tetracycline has
been advocated for suppression of urinary infection with pseu-
domonas species [161. As with penicillin, achievable urinary
concentrations of tetracycline inhibit most strains of pseudomo-
nas. The benefit of antimicrobial agents such as sulfas, nitrofur-
antoins, and methenamine salts is undocumented.
Drugs that inhibit urease may retard growth of infection-
induced stones. At present, however, no urease-inhibiting
drugs have been approved by the Food and Drug Administra-
tion. Preliminary evidence suggests that concomitant treatment
with antimicrobial agents and urease-inhibitor drugs may re-
suit in greater inhibition of stone formation than with either
drug alone [17].
Kobashi, Hase, and Uehara showed in 1962 that the hydroxa-
mic family of compounds effectively inhibited urease [18]. In
1970, Fishbein and Daly reported studies involving the struc-
ture, enzyme inhibitory potency, and relative toxicity of short-
chain aliphatic hydroxamic acids [191. They concluded that
acetohydroxamic acid, more than any of the other hydroxamic
acids tested, offered the greatest pharmacologic promise. Ex-
perimental studies show that urease inhibitors can prevent or
retard infection-induced stone formation [8, 9, 201. The efficacy
of therapy depends on achievement of therapeutic urinary
concentrations of the urease inhibitor. At least four compounds
are undergoing evaluation (Fig. 4) [9, 17, 20—24].
Hydroxyurea, commercially available as an antitumor agent,
has received little attention as a urease inhibitor. Preliminary
clinical trials indicate, however, that its tendency to cause
leukopenia and its weak urease-inhibiting properties limit its
usefulness in patients with infection-induced stones [211.
Acetohydroxamic acid (AHA), which is weakly acidic (pK =
9.3) and is structurally similar to urea, forms a tight, noncom-
petitive, slowly reversible bond with urease. It also chelates
iron. Highly soluble in water, AHA is distributed throughout
body water and is rapidly and completely absorbed from the
gastrointestinal tract [25]; 30% to 60% of the drug is excreted
unchanged in urine. Urinary concentrations of AHA achievable
by oral administration provide no significant antimicrobial
activity. Approximately 10% of an oral dose of AHA is metabo-
lized to acetamide, which is excreted in the urine, and another
10% of an oral dose is metabolized to carbon dioxide (Feldman
S, Griffith DP, unpublished data). Protein binding has not been
demonstrated. Renal failure results in an accumulation of AHA
and perhaps also its metabolite acetamide. Research has shown
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Fig. 2. Changes in urinary solutes in sterile urine inoculated with bacterial urease. Increases in alkalinity and solute concentrations brought about
supersaturation with respect to calcium phosphate and magnesium ammonium phosphate. These substances crystallized rapidly. (Reproduced
from Ref. 11.)
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Table 1. Microbial species that produce ureasea
Usually Occasionally
Organism (>90% of isolates) (5%—30% of isolates)
Bacteria Gram-positive
Staphylococcus aureus Staphylococcus epidermidis
Micrococcus varians Bacillus species
Corynebacterium ulcerans Corynebacterium munum
Corynebacterium renale Corynebacterium equi
Corynebacterium ovis Peptococcus saccharolyticus
Corynebacterium hofmannii Clostridium tetani
Mycobacterium rhodochrous group
Gram-negative
Proteus rettgeri Klebsiella pneumoniae
Proteus vulgaris Kiebsiella oxytoca
Proteus mirabilis Serratia marcescens
Proteus morgani Hemophilus parainfluenzae
Providencia stuartii Bordetella bronchiseptica
Providencia rettgeri Aeromonas hydrophila
Enterobacter gergoviae Pseudomonas aeruginosa
Hemophilus influenzae Pasteurella species
Bordetella pertussis
Bacteroides corrodens
Yersinia enterocolitica
Brucella species
Flavobacterium species
Pasteurella aerogenes
Yeasts
Cryptococcus
Rhodotorula
Sporobolomyces
Candida humicola
Trichosporon cutaneum
Mycoplasma
T-strain mycoplasma
Analytab Products Inc., 200 Express Street, Plainview, New York 11803. Data from Cowan ST, Steele KJ: Manual for the Ident/ication of
Medical Bacteria, p. 238, Cambridge, Cambridge University Press, 1974; from Ford DK: Inhibitioh of growth of T-strain mycoplasmas by
hydroxamic acids and by aurothiomalate. Antimicrob Agents Chemot her 2:340, 1972; and from Seeliger HPR: Use of a urease test for the screening
and identification of cryptococci. J Bacteriol 72:127, 1956. Reproduced from Nephrolithiasis, Contemporary Issues in Nephrology, vol. 5, edited
by Fredric L. Coe, M.D., Barry M. Brenner, M.D., and Jay H. Stein, M.D. Copyright © 1980 by Churchill Livingstone. Reprinted by permission of
Churchill Livingstone, New York.
AHA to be a weak teratogen in animals [26]. Although no
carcinogenic activity has been demonstrated for AHA [271,
acetamide is a weak carcinogen in mice [28].
We have given an oral dose of approximately 15 mg/kg/day of
AHA to more than 70 patients in an effort to inhibit stone
formation in the presence of an incurable urea-splitting infec-
tion. Details of the study have been reported elsewhere [24].
Virtually all patients sustained a reduction in ammoniuria and
urinary alkalinity (Fig. 5). Stone growth was studied in patients
treated with AHA (Group C), compared with the same patients
before treatment (Group B), or after treatment (Group D).
These patients also were compared with untreated controls
(Group A). The AHA-treated group had statistically less stone
formation than did any of the control groups (Figs. 6 and 7)
(Griffith DG, unpublished data). Side effects consisted of gas-
trointestinal upset, malaise, phlebitis, tremulousness, loss of
body hair, and a hemolytic anemia (Table 2). In most instances,
the side effects did not warrant discontinuation of treatment,
although we did sometimes reduce the dosage. In many in-
stances, a cause-and-effect relationship between the reported
symptoms and AHA treatment could not be definitely estab-
lished. It is likely, however, that the hemolytic anemia, the
tremulousness, the rash associated with alcohol ingestion, and
the alopecia were drug induced. These abnormalities reversed
when treatment was discontinued.
Urease-inhibiting drugs are not likely to dissolve large stag-
horn stones nor to replace surgical and antimicrobial therapy.
Urease inhibitors seem best suited for long-term palliative
treatment of the patient with recalcitrant urea-splitting infec-
tion, reasonably good renal function, and little or no obstruction
to urinary flow. In such patients urease-inhibitors retard calcul-
logenesis. It is likely that AHA will be ineffective in patients
whose serum creatinine is greater than 2.0 mg/dl; also, the risk
of side effects probably increases in patients with poor renal
function. The ultimate role of urease-inhibiting drugs in the
therapeutic armamentarium will be determined by clinical expe-
rience that seeks to balance the risks and benefits of treatment
with the risks of the patient's disease.
Questions and answers
DR. JOHN T. HARRINGTON: What specific surgical approach
would you recommend in a patient such as the one presented
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Fig. 4. Molecular structures of urea and urease inhibitors.
Fig. 5. Changes in urinary pH and ammonia in 23 patients during long-
term treatment with AHA at a dose of 1.0 glday. Open circles denote
urinary pH and ammonia prior to AHA treatment. Closed circles denote
urinary pH and ammonia while on AHA. Rectangle encloses SEM for
ammonia and pH values in normal subjects (N = 20) with sterile urine.
(Reproduced from Griffith DP, Gibson JR, Clinton CW, Musher DM:
Acetohydroxamic acid: Clinical studies of a urease inhibitor in patients
with staghorn renal calculi. J Urol 119:9—15, 1978; © The Williams and
Wilkins Co., Baltimore.)
today who has a serum creatinine concentration of 2.5 to 3.0
mgldl? Are any intraoperative strategies available today that
were unknown, say, 10 years ago?
DR. GRIFFITH: As a rule, I would operate first on the kidney
that is going to have the least benefit—in this case, the right
kidney, which may have xanthogranulomatous pyelonephritis.
If there is little improvement of renal function, the patient
hasn't lost very much. If improved function results from the
operation, the margin of safety is improved as I operate on the
better kidney. Complete mobilization of the kidney will be
C
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required, and this is likely to require an incision at the eleventh
rib. I would try to remain extrapleural, but there is high
probability that the pleural space will be entered. A pyelolitho-
tomy is unlikely to yield all of the stones. Therefore, I would
perform a nephrolithotomy through the parenchyma. I also
would utilize renal ischemia and hypothermia. Recently I have
been inserting ureteral catheters preoperatively and instilling a
coagulum composed of cryoprecipitate, thrombin, and calcium
into the pyelocalyceal system. Often the soft, mushy, poorly
mineralized matrix, an integral component of these stones,
becomes trapped in this gelatinous coagulum. This method
assists in the removal of debris. Before completing the proce-
dure, I would take intraoperative radiographs to be sure that all
of the stone had been removed. Finally, I would leave a
nephrostomy tube in the kidney and would use the tube
postoperatively to measure renal function and to lavage the
pyelocalyceal system with an acidic stone solvent. After a few
weeks I would approach the left kidney if the patient had done
well.
DR. HARRINGTON: Dr. Meares, you have had an opportunity
to examine this patient. Taking into account her weight of 100
kg and the complexities of this exceedingly difficult case, what
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Fig. 6. Incidence of stone growth in stone-containing kidneys. Group A
is untreated controls, Group B is pre-AHA treatment controls, Group C
is AHA treatment group. N = 40, 42, and 32 respectively for Groups A,
B, and C.
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Fig. 7. Stone growth rate in 40 patients paired against themselves.Group B = Prior to AHA treatment; Group C = During AHA
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Table 2. Possible side effects of acetohydroxamic acid therapy
% Patients
Headache 75
Gastrointestinal upset 50
Anemia (mild) 17
Phlebitisb 13
Loss of hair 10
Rash with consumption of alcohol 8
Tremulousness 4
Anemia (severe) 3
Pulmonary emboli" 1.4
a Seventy-six patients were treated for 1309 patient months [23].
b Phlebitis was endemic in the study population, which contained a
large population of patients with spinal cord injury. A cause-and-effect
relationship with AHA treatment is doubtful.
are your thoughts and how do you manage patients with
staghorn calculi?
DR. EDWIN M. MEARES, JR. (Chairman, Department of
Urology, NEMC): When I saw her initially I thought the right
kidney was not operable because I too believed it demonstrated
xanthogranulomatous pyelonephritis. In such cases the dense
inflammatory tissue surrounding the kidney often makes per-
formance of anatrophic nephrolithotomy impossible. We had
planned to explore the left kidney, provided the patient lost
sufficient weight to make a transpleural approach unnecessary.
Her body habitus was such that I believed the only way one
could safely approach that kidney—mobilize it completely and
obtain control of its blood supply—was through a thoracoabdo-
minal incision. Although I use this approach routinely for large
renal tumors, in this patient I did not want to risk a chest
infection due to proteus and death from complications of
surgery. Our plan was to manage her as an outpatient with diet
and antibiotics in the hope that she would lose about 50 pounds;
then we would operate. Unfortunately, she gained weight on
this diet. Although I agree with Dr. Griffith that this patient's
chances of surviving for very long without successful stone
removal or dissolution are not good, I finally decided that she
was not sufficiently motivated to lose the necessary weight to
allow us to undertake surgical intervention safely.
My surgical technique in managing staghorn calculi is similar
to the approach described by Dr. Griffith. The operation was
popularized by Dr. William Boyce at Bowman Gray and usually
is referred to as an anatrophic nephrolithotomy. The kidney is
mobilized completely, the renal artery controlled, and the
kidney cooled. A non-crushing vascular clamp is placed across
the artery (the vein is usually left open); a nephrotomy incision
allows the surgeon wide access to the renal pelvis and calices
through the parenchyma with minimal blood loss. With renal
hypothermia one can keep the renal artery clamped continuous-
ly for more than an hour. We always leave a nephrostomy tube
in place to irrigate the kidney postoperatively with Renacidin®
solution. In our experience, postoperative irrigation is an
extremely important component of any operation on a staghorn
calculus. Almost always, little fragments of stone that one
cannot see on x-ray film are left attached to the urothelium and
papillae following nephrolithotomy. This will cause the opera-
tion to fail because these infected particles serve as a nidus for
re-formation of the staghorn.
DR. HARRINGTON: Dr. Griffith, would you comment about
Renacidin®? What are your indications for its use?
DR. GRIFFITH: We use Renacidin® commonly but not rou-
tinely. If the stone is hard and can be removed intact without
fragmentation, I do not use a nephrostomy tube or irrigation. If
the stone is mushy, or if it is fragmented during extraction, I
irrigate postoperatively with Renicidin® through a nephrostomy
tube.
DR. JERRY BLAIVAS (Department of Urology, NEMC): If the
decision in this case was to remove the stones on the left side
only, would you think it important to remove the right kidney to
lower the likelihood of recurrent proteus infection?
DR. GRIFFITH: Yes.
DR. HARRINGTON: What about using Renacidin® preoper-
atively?
DR. GRIFFITH: We have had no experience with this ap-
proach. Drs. Dretler, Pfister, and Newhouse from the Massa-
chusetts General Hospital recently reported a favorable experi-
ence with percutaneous lavage of staghorn calculi using Renaci-
din® [291. Dr. Heaney was on the staff at the M.G.H, during that
time and might be able to provide more information.
DR. JOHN A. HEANEY (Department of Urology, NEMC): One
of the problems with these patients was that although we could
remove the radiologically obvious stone, we sometimes were
unable to remove the matrix, Two of our patients at Tufts had
stones on one side that we thought we could remove surgically,
but each had a stone on the other side, in a kidney previously
operated on, that we thought would be exceedingly difficult to
approach surgically. We have a follow-up of one year on one
patient in whom we completely dissolved the stones on the
previously operated side with percutaneous nephrostomy and
Renacidin® only. There are selected instances in which percuta-
neous stone dissolution can be accomplished, but we must keep
in mind that stone dissolution with these methods is often
complicated by recurrent infection and pain. Weeks of hospital-
ization may be required in patients in whom the expeditious
surgical removal of the calculus or kidney would have the
patient out of the hospital in 10 days.
DR. HARRINGTON: I believe that there are other ways of
breaking up staghorn calculi, such as ultrasonic destruction of
the stone. Could you comment on this new approach, Dr.
Griffith?
DR. GRIFFITH: New technology is being developed in Europe
that may permit "in situ" stone disintegration utilizing hydro-
dynamic shock waves without surgery [30, 31]. Another Euro-
pean approach utilizes operative nephroscopy combined with
electrohydraulic lithotripsy [321. Both of these approaches
appear promising but are still investigational.
DR. JAMES STROM (Renal Service, St. Elizabeth's Hospital,
Boston, Mass.): What are your usual indications for surgical
therapy in patients with staghorn calculi? Because recurrent
stones are common even with good surgical therapy and
because one occasionally can sterilize the urine with antibiot-
ics, some nephrologists simply treat with antibiotics and follow
the patient carefully. If the urine is sterilized and if there isn't
progressive renal insufficiency, surgery is not used. What do
you think of that approach?
DR. GRIFFITH: I believe the approach to cancer treatment is
analagous. If a patient presents with a malignant disease, do
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you offer curative therapy, or do you offer palliative therapy?
DR. STROM: What I'm asking is how do you know whether
you're dealing with 'malignant stone disease"?
DR. GRIFFITH: All infection-induced stones are a potentially
malignant disease. I believe that all patients with renal stones
and a chronic urea-splitting urinary infection should be offered
curative surgical treatment if they are reasonable candidates for
operation.
DR. MEARES: I would like to add a comment. I believe that
the cure rate following surgical treatment of staghorn calculi in
the usual patient, not the patient presented, is probably much
higher than 80% when the procedure is performed correctly. I
believe that it is not in the patient's best interest to treat by
medical suppression a condition that can be cured about 90% of
the time by an operation in which the risk of death or loss of
kidney function is very low.
DR. GRIFFITH: I agree.
DR. BARRY STRAUBE (Renal Fellow, NEMC): You comment-
ed that some staghorn calculi originate from a calcium oxalate
stone or uric acid stone. Do you recommend thiazide or
allopurinol therapy in these patients?
DR. GRIFFITH: Appropriate medical therapy is warranted and
may consist of dietary alterations, drug treatment, or both.
Stone analysis and biochemical evaluation of blood and urine
should point the way toward appropriate medical treatment. I
favor postoperative biochemical evaluation. The Mayo Clinic
has reported a 50% incidence of underlying metabolic stones in
patients with infectious stones [33]. Drs. Boyce and Resnick
recently reported a 50% incidence of mixed stones in a series of
patients with staghorn calculi [34]. Interestingly, preoperative
metabolic studies had detected essentially nothing other than
infection to account for the stones. When the metabolic studies
were repeated postoperatively after the urine had been ren-
dered sterile, a high incidence of hypercalciuria and hyperurico-
suria was found. These findings probably can be explained by
the improvement in renal function consequent to elimination of
stones and infection.
DR. ANDREW LEVEY (Renal Service, NEMC): You have
clarified the pathogenesis of the infection-induced stone. Would
you speak for a moment on what causes infection-associated
stones? Do the bacteria in urine nucleate stones in patients
whose urine is already supersaturated with minerals such as
calcium or urate, or do stones allow a nidus of bacterial
infection to persist?
DR. GRIFFITH: I believe that urinary infection and stones are
separate entities. Sometimes they coexist in the same patient. A
stone that becomes infected can harbor and perpetuate the
infection, but the stones themselves do not cause infection.
Only urease-producing bacteria cause calculogenesis.
DR. STEVEN ZELMAN (Renal Fellow, NEMC): You have
shown that AHA reduces both the urinary pH and the ammoni-
urn concentration, presumably as a result of a reduction in
urease activity. If antibiotics are suppressing bacterial growth
and urease production, what additional benefit does AHA
provide?
DR. GRIFFITH: If sterile urine can be achieved with antibiot-
ics, AHA may not be needed. If consistent sterility cannot be
achieved, then concomitant treatment (with antibiotics and
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